Johnson & Johnson’s growth rate
Johnson & Johnson (JNJ) reported a rise of ~0.8% in revenues in constant currencies for 3Q15 over 3Q14. The company’s 3Q15 revenues were $17.1 billion, lower than analysts’ estimates of $7.4 billion.
Impact of foreign exchange rates
The above graph shows that foreign exchange rates had a constant negative impact on the growth rate of Johnson & Johnson in each quarter. This is mainly because ~50% of total revenues of Johnson & Johnson are reported from sales outside the United States. The company operates ~134 manufacturing facilities and eight innovation and research centers worldwide.
Johnson & Johnson’s revenues have risen over past few year following the restructuring of its business segments and strong performance of few of its key products including Xarelto, Zytiga, Remicade, Stelara, and Olysio. The 2014 revenues rose by ~4.2% to $74.3 billion, compared to $71.3 billion for 2013.
We’ll discuss 3Q15’s segment-wise revenues and performance in coming articles.
Johnson and Johnson’s revenues fell by ~7.4% in 3Q15 as compared to 3Q14, while the results for other companies are still awaited as on date. VanEck Vectors Pharmaceutical ETF (PPH) invests 7.4% of its portfolio in Johnson & Johnson, 7.9% in Novartis AG (NVS), 5.6% in Pfizer (PFE), and 5.0% in Merck and Co. (MRK). Investors can refer to earnings of other companies on our pharmaceutical earnings overview page.